METIS TECHBIO-P stock plummeted 7.10% during intraday trading on Monday, continuing a downward trend that began after the company's blockbuster market debut.

The decline reflects a cooling of investor enthusiasm following the stock's extraordinarily hot debut, where it surged 173% from its IPO price. Market participants note that certain international placement shares carry no lock-up period, creating selling pressure as early investors look to realize gains from the dramatic first-day pop.

The company, dubbed the first global AI drug delivery stock, remains in early-stage commercialization with approximately 1.5 billion yuan in accumulated losses over three years and volatile revenue performance. The stock has now retreated significantly from its intraday high recorded on its listing day.